World

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor
AJMC Contributor
0 Min Read
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).

This post was originally published on this site

Previous Article Growing conservative movement in Canada is fighting back against ‘California on steroids,’ says strategist
Next Article Elon Musk Is Trying to Break Germany’s Quarantine on the Far-Right AfD
This shift could unify the various factions within the party—moderates and progressives alike—around a common cause. : it's imperative to consult a healthcare provider when considering constipation treatment during pregnancy. Sam altman and the future of ai technology.